The study will be conducted in collaboration with CA Clinics and is one of the first of its kind globally.

A new study aimed at assessing the efficacy of THC-based medications for sufferers of cachexia was launched this week by Applied Cannabis Research (ACR), a division of Southern Cannabis Holdings (SCH).

Read more: